Last reviewed · How we verify
ASP2998
At a glance
| Generic name | ASP2998 |
|---|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP2998 CI brief — competitive landscape report
- ASP2998 updates RSS · CI watch RSS
- Astellas Pharma Global Development, Inc. portfolio CI